Literature DB >> 25769726

Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.

Caroline I Schnegg1, Moon Hee Yang1, Subrata K Ghosh1, Mei-Yu Hsu2.   

Abstract

The basis for resistance to VEGF inhibition is not fully understood despite its clinical importance. In this study, we examined the adaptive response to VEGF-A inhibition by a loss-of-function analysis using plasmid-based shRNA. Tumor xenografts that initially responded to VEGF-A inhibition underwent an adaptation in vivo, leading to acquired resistance. VEGF-A blockade in tumors was associated with HIF1α expression and an increase in CD144(+) vasculogenic mimicry (VM), leading to formation of channels displaying Tie-1 and MMP-2 upregulation. CD133(+) and CD271(+) melanoma stem-like cells (MSLC) accumulated in the perivascular niche. Tumor xenografts of melanoma cell populations that were intrinsically resistant to VEGF-A blockade did not exhibit any of these features, compared with nontarget control counterparts. Thus, melanomas that are initially sensitive to VEGF-A blockade acquire adaptive resistance by adopting VM as an alternate angiogenic strategy, thereby enriching for deposition of MSLC in the perivascular niche through an HIF1α-dependent process. Conversely, melanomas that are intrinsically resistant to VEGF-A blockade do not show any evidence of compensatory survival mechanisms that promote MSLC accumulation. Our work highlights the potential risk of anti-VEGF treatments owing to a selective pressure for an adaptive resistance mechanism that empowers the development of stem-like cancer cells, with implications for how to design combination therapies that can improve outcomes in patients. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25769726      PMCID: PMC4401656          DOI: 10.1158/0008-5472.CAN-14-1855

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Neuroscience. Cellular interactions in the stem cell niche.

Authors:  Andrew E Wurmser; Theo D Palmer; Fred H Gage
Journal:  Science       Date:  2004-05-28       Impact factor: 47.728

3.  VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.

Authors:  Natasha Y Frank; Tobias Schatton; Soo Kim; Qian Zhan; Brian J Wilson; Jie Ma; Karim R Saab; Veronika Osherov; Hans R Widlund; Martin Gasser; Ana-Maria Waaga-Gasser; Thomas S Kupper; George F Murphy; Markus H Frank
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

4.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

5.  Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation.

Authors:  Mei-Yu Hsu; Sherry A Rovinsky; Chiou-Yan Lai; Shadi Qasem; Xiaoming Liu; Joan How; John F Engelhardt; George F Murphy
Journal:  Lab Invest       Date:  2008-06-16       Impact factor: 5.662

6.  CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.

Authors:  Chiou-Yan Lai; Brian E Schwartz; Mei-Yu Hsu
Journal:  Cancer Res       Date:  2012-08-03       Impact factor: 12.701

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  From cancer stem cells to tumor maintenance in melanoma.

Authors:  Mizuho Fukunaga-Kalabis; Alexander Roesch; Meenhard Herlyn
Journal:  J Invest Dermatol       Date:  2011-06-09       Impact factor: 8.551

9.  Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures.

Authors:  Klara Valyi-Nagy; Bernadett Kormos; Mohamed Ali; Deepak Shukla; Tibor Valyi-Nagy
Journal:  Mol Vis       Date:  2012-03-02       Impact factor: 2.367

10.  Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells.

Authors:  Xiaohong Yao; Yifang Ping; Ying Liu; Kequiang Chen; Teizo Yoshimura; Mingyong Liu; Wanghua Gong; Chong Chen; Qin Niu; Deyu Guo; Xia Zhang; Ji Ming Wang; Xiuwu Bian
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more
  36 in total

1.  Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype.

Authors:  Lingli Yao; Danfang Zhang; Xiulan Zhao; Baocun Sun; Yanrong Liu; Qiang Gu; Yanhui Zhang; Xueming Zhao; Na Che; Yanjun Zheng; Fang Liu; Yong Wang; Jie Meng
Journal:  J Cell Mol Med       Date:  2016-05-31       Impact factor: 5.310

2.  [Mig-7 gene silencing inhibits vasculogenic mimicry formation and invasion of glioma U251 cells in vitro by suppressing MEK/ERK signaling].

Authors:  Fan Wang; Fenglong Chen; Weipeng Hu; Yi Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

3.  Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.

Authors:  Hai-Bo Wu; Shuai Yang; Hai-Yan Weng; Qian Chen; Xi-Long Zhao; Wen-Juan Fu; Qin Niu; Yi-Fang Ping; Ji Ming Wang; Xia Zhang; Xiao-Hong Yao; Xiu-Wu Bian
Journal:  Autophagy       Date:  2017-08-16       Impact factor: 16.016

4.  Evaluation of Pharmaceutical Inhibition of Vasculogenic Mimicry In Vitro.

Authors:  Joseph C Manarang; Alison McDermott
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry.

Authors:  Elena Andreucci; Silvia Peppicelli; Jessica Ruzzolini; Francesca Bianchini; Lido Calorini
Journal:  Cancer Metastasis Rev       Date:  2022-10-13       Impact factor: 9.237

6.  Growth of Uveal Melanoma following Intravitreal Bevacizumab.

Authors:  Jasmine H Francis; Jonathan Kim; Amy Lin; Robert Folberg; Saipriya Iyer; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2016-11-12

Review 7.  Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jun-Tzu Chao; Du-Shieng Chien; Yi-Wen Chu
Journal:  Pharmacol Ther       Date:  2016-01-22       Impact factor: 12.310

8.  Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.

Authors:  Xin Mei; Yin-Sheng Chen; Fu-Rong Chen; Shao-Yan Xi; Zhong-Ping Chen
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

9.  Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.

Authors:  Nathaniel R Campbell; Anjali Rao; Miranda V Hunter; Magdalena K Sznurkowska; Luzia Briker; Maomao Zhang; Maayan Baron; Silja Heilmann; Maxime Deforet; Colin Kenny; Lorenza P Ferretti; Ting-Hsiang Huang; Sarah Perlee; Manik Garg; Jérémie Nsengimana; Massimo Saini; Emily Montal; Mohita Tagore; Julia Newton-Bishop; Mark R Middleton; Pippa Corrie; David J Adams; Roy Rabbie; Nicola Aceto; Mitchell P Levesque; Robert A Cornell; Itai Yanai; Joao B Xavier; Richard M White
Journal:  Dev Cell       Date:  2021-09-15       Impact factor: 12.270

10.  Endothelial cell-specific redox gene modulation inhibits angiogenesis but promotes B16F0 tumor growth in mice.

Authors:  Yoshimitsu Yura; Brian S H Chong; Ryan D Johnson; Yosuke Watanabe; Yuko Tsukahara; Beatriz Ferran; Colin E Murdoch; Jessica B Behring; Mark E McComb; Catherine E Costello; Yvonne M W Janssen-Heininger; Richard A Cohen; Markus M Bachschmid; Reiko Matsui
Journal:  FASEB J       Date:  2019-10-26       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.